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Background. Nondaily dosing of oral preexposure prophylaxis (PrEP) may provide equivalent coverage of sex events compared 
with daily dosing.
Methods. At-risk men and transgender women who have sex with men were randomly assigned to 1 of 3 dosing regimens: 1 tablet 
daily, 1 tablet twice weekly with a postsex dose (time-driven), or 1 tablet before and after sex (event-driven), and were followed for cover-
age of sex events with pre- and postsex dosing measured by weekly self-report, drug concentrations, and electronic drug monitoring.
Results. From July 2012 to May 2014, 357 participants were randomized. In Bangkok, the coverage of sex events was 85% for the 
daily arm compared with 84% for the time-driven arm (P = .79) and 74% for the event-driven arm (P = .02). In Harlem, coverage was 
66%, 47% (P = .01), and 52% (P = .01) for these groups. In Bangkok, PrEP medication concentrations in blood were consistent with 
use of ≥2 tablets per week in >95% of visits when sex was reported in the prior week, while in Harlem, such medication concentra-
tions occurred in 48.5% in the daily arm, 30.9% in the time-driven arm, and 16.7% in the event-driven arm (P < .0001). Creatinine 
elevations were more common in the daily arm (P = .050), although they were not dose limiting.
Conclusions. Daily dosing recommendations increased coverage and protective drug concentrations in the Harlem cohort, 
while daily and nondaily regimens led to comparably favorable outcomes in Bangkok, where participants had higher levels of edu-
cation and employment.
Clinical Trials Registration.  NCT01327651.
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Daily dosing of preexposure prophylaxis (PrEP) is recom-
mended by the US Food and Drug Administration and the 
Centers for Disease Control and Prevention [1], whereas the 
European AIDS Clinical Society recommends either daily dos-
ing or dosing before and after sex [2]. The Ipergay trial demon-
strated effectiveness of “on demand” dosing, involving a double 
emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) dose 
2–24 hours before sex and an additional FTC/TDF dose on each 
of the 2 days following sex [3], confirming findings from ani-
mal models [4]. The Iniciativa Profilaxis Pre-exposición (iPrEx) 
open-label extension found no new infections among men with 
drug concentrations indicating the use of ≥4 tablets of FTC/
TDF per week as well as an 81% reduction in human immuno-
deficiency virus (HIV) incidence associated with average use of 
2–3 tablets per week [5].
Adherence to event-driven dosing recommendations has 
been mixed. Such dosing was associated with lower PrEP 
adherence in 2 small blinded and placebo-controlled PrEP tri-
als conducted in Africa [6, 7]. The use of blinding and a placebo 
may have undermined PrEP use in these trials. Furthermore, 
different measurements provided highly divergent estimates of 
adherence, which highlighted the methodological challenges 
arising when assessing event-driven PrEP dosing.
The HIV Prevention Trials Network (HPTN) study 067, the 
Alternative Dosing to Augment PrEP Pill Taking (ADAPT) 
study, randomly assigned participants to daily or nondaily 
dosing of open-label oral FTC/TDF. The aim was to assess the 
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likelihood that sex events would be covered by pre- and post-
exposure antiretroviral dosing with daily or nondaily regimens 
that were effective in animal models [4] and the likelihood of 
achieving drug concentrations that provide substantial reduc-
tions in HIV incidence among men and transgender women 
who have sex with men [5].
METHODS
Study Design
The HPTN 067 study was a phase 2, randomized, open-label, 
pharmacokinetic, and behavioral equivalence study of daily 
vs nondaily oral FTC/TDF PrEP. The study enrolled men and 
transgender women who have sex with men at a community 
clinic and clinical research site in Bangkok, Thailand, and a 
clinical research site in Harlem in New York City. Women were 
enrolled at a study site in Cape Town, South Africa, as reported 
separately [8]. Ethics committee approvals were obtained 
from all applicable authorities (see Supplementary Materials). 
The protocol was registered at ClinicalTrials.gov (identifier 
NCT01327651; https://www.hptn.org/research/studies/82).
Participants
Participants were eligible based on the following criteria: male 
sex assigned at birth, HIV-antibody negative, at least 18 years 
old, normal renal function (estimated creatinine clearance 
>70 mL/minute), hepatitis B surface antigen negative, literate in 
English or Thai, able to provide written informed consent, and 
reported anal or neovaginal sex with a man in the past 6 months, 
and have at least 1 of the following self-reported risk factors 
for HIV acquisition in the past 6 months: sex with >1 man or 
transgender woman; history of an acute sexually transmitted 
infection; sex in an exchange for money, goods, or favors; or 
intercourse without a condom with an HIV-infected partner or 
partner of unknown HIV infection status (see Supplementary 
Materials for eligibility related to hepatitis B immunity).
Visits and Medication Dispensation
Study visits were divided into phases for screening, directly 
observed dosing, self-administered dosing, and post-PrEP use. 
Visits were scheduled at screening; enrollment (the beginning 
of directly observed dosing); weeks 1, 2, 3, and 4 (the end of 
directly observed dosing); weeks 5 and 6 (randomization and 
the beginning of self-administered dosing); weeks 10, 14, 18, 
22, 26, and 30 (end of self-administered dosing); and week 34. 
To facilitate interpretation of drug concentration results during 
the study, participants received once per week directly observed 
dosing of 1 tablet of oral FTC/TDF at enrollment and at weeks 
1, 2, 3, and 4. At week 6, participants were randomized and were 
dispensed 30 tablets of oral FTC/TDF and provided counseling 
specific to their randomization group (see Supplementary 
Materials). Every 4 weeks during the self-administered phase, 
an additional 30 tablets of FTC/TDF were dispensed.
Monitoring of PrEP Use and Sex
All participants received a real-time electronic drug monitor-
ing (EDM) device (WisePill) at enrollment. Weekly phone-
based or in-person interviews at the study site (at the choice 
of the participant) were conducted using real-time EDM data 
to determine if an electronically recorded “opening” event was 
reflective of an ingested dose (vs curiosity opening, pocket 
dose, or refill of device) and for correction of date and time 
for doses removed and taken at a later time; after collecting 
dose date and time information, sexual events over the past 
week were documented for date and time, as well as type of 
sex, condom use, and partners. Interviewers were not part of 
the clinical care team and did not feed back information to 
team members and were trained in neutral interviewing [9]. 
The results of the EDM-guided weekly interviews formed the 
basis for assessing coverage of sex events with pre- and postex-
posure dosing and adherence (see Supplementary Materials). 
Participants were offered vitamin tablets during the 6-week 
directly observed therapy phase (to become familiar with the 
device). Long-term adherence to PrEP was evaluated using 
blood concentrations of tenofovir diphosphate (TFV-DP) in 
dried blood spots [5, 10] or peripheral blood mononuclear 
cells [11] (see Supplementary Materials). Tablet sharing was 
investigated by a computer-assisted self-interview conducted 
12 and 24 weeks after randomization.
Primary Outcomes
The primary outcome was coverage of anal and neovaginal 
intercourse events with pre- and postexposure dosing of PrEP 
defined as at least 1 tablet reported taken within 96 hours 
(4 days) prior to intercourse and another tablet reported taken 
within 24 hours after intercourse. Drug concentrations during 
weeks when sex was reported should reflect use of at least 2 
PrEP tablets if the sex event was covered with pre- and postsex 
dosing according to the regimens recommended in the proto-
col. This amount of oral FTC/TDF PrEP use protected non-
human primates [4] and reduced HIV incidence in men who 
have sex with men (MSM) by 76% [11]. See the Supplementary 
Materials for definitions of outcomes.
Statistical Analysis
Quantitative measures are summarized using medians and 
interquartile ranges; categorical measures are summarized with 
proportions. In the primary analysis of coverage, the unit of 
analysis is the sex act (covered or not covered). A logistic regres-
sion for dependent data [12] with robust variance and cluster-
ing on participant was used to compare coverage between the 
daily arm and each intermittent arm (P values for a standard 
inequality test are given and we comment on noninferiority as 
needed). A similar approach (with the follow-up visit as the unit 
of analysis) was used to compare the prevalence of neurological 
and gastroenterological side effects between arms. The number 
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Figure 1. Consort diagrams for the HIV Prevention Trials Network (HPTN) 067 ADAPT study in Bangkok, Thailand (A) and Harlem, New York (B). Abbreviations: ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; DOT, directly observed therapy; HBV, hepatitis B virus; HIV, human immunodeficiency virus; Ser Cr, serum creatinine.
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/cix1086/4840078
by Columbia University user
on 01 March 2018
4 • CID 2018:XX (XX XXXX) • Grant et al
of pills used and the number of pills required to achieve full 
adherence to the recommended regimens were compared using 
a log regression with offset equal to the log of the duration of 
follow-up and a robust variance. All analyses were intent to 
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RESULTS
Study Participants
From 4 July 2012 to 6 May 2014, 608 people were screened, 431 
were enrolled, and 357 (83%) were randomized and included 
in the analysis (Figure  1A and 1B). One randomized partici-
pant in Bangkok was excluded from the analysis, as instructed 
by the local institutional review board, due to a protocol devi-
ation. Retention through the end of the self-administered dos-
ing phase (week 30) was 97% at the Bangkok site and 83% at the 
Harlem site. Overall, among people randomized, 350 identified 
as a man, 5 identified as a transgender woman, and 2 identified 
as gender queer (Table 1). Participants in Bangkok were more 
likely than those in Harlem to have at least secondary educa-
tion (P < .0001) and be fully employed (P < .0001). Among the 
179 participants in Harlem, race/ethnicity was self-reported in 
nonexclusive categories: 126 (70%) were black, 23 (13%) were 
white, 5 (3%) were Asian, 5 (3%) were Native American, 44 
(25%) were Hispanic, and 37 (21%) were other.
Coverage and PrEP Use
Overall, 357 people reported 7734 sex events during the 
24-week self-administered phase (average 0.9 sex events per 
person per week). In Bangkok, coverage of sex events was 85% 
(1266/1485) for the daily arm compared with 84% (1129/1337) 
for the time-driven arm (P = .79 vs daily), and 74% (749/1018) 
for the event-driven arm (P  =  .02 vs daily) (Figure  2A). In 
Harlem, coverage was 66% (718/1081) for the daily arm com-
pared with 47% (615/1311) for the time-driven arm (P = .01 vs 
daily) and 52% (786/1502) for the event-driven arm (P  =  .01 
vs daily) (Figure 2B). Among people with partial coverage, the 
postsex dose was more commonly missed than the presex dose 
at both sites (Figure 2). Coverage did not change over time in 
any arm at either site (P = .98 for Bangkok, P = .20 for Harlem; 
Figure 3). The results were not different when coverage of sex 
events without a condom was considered.
In Bangkok, TFV-DP concentrations in peripheral blood 
mononuclear cells suggested use of ≥2 tablets on visits when 
sex was reported in the prior week among 97.6% in the daily 
arm, 98.7% in the time-driven arm (P = .60 vs daily), and 95.7% 
in the event-driven arm (P = .51 vs daily) (Table 2). In Harlem, 
TFV-DP concentrations in dried blood spots suggested use of 
≥2 tablets on visits when sex was reported in the prior week 
among 48.5% in the daily arm, 30.9% in the time-driven arm 
(P = .11 vs daily), and 16.7% in the event-driven arm (P = .004 
Table 1. Baseline Characteristics Among Participants Randomized in the HIV Prevention Trials Network (HPTN) 067 Study, Bangkok, Thailand (n = 178) 
and Harlem, New York (n = 179)
Characteristic
Bangkok Harlem
Daily Time-Driven Event-Driven Daily Time-Driven Event-Driven
Age, y
 18–24 8 (13.3) 12 (20.3) 8 (13.5) 19 (32.2) 17 (28.3) 17 (28.3)
 25–29 13 (21.7) 19 (32.2) 16 (27.1) 13 (22.0) 11 (18.4) 8 (13.4)
 30–39 36 (60.0) 23 (39.0) 28 (47.5) 11 (18.7) 12 (20.0) 14 (23.3)
 ≥40 3 (5.0) 5 (8.5) 7 (11.9) 16 (27.1) 20 (33.3) 21 (35.0)
Self-identified gender
 Man 59 (98.3) 58 (98.3) 59 (100) 57 (96.6) 59 (98.3) 58 (96.6)
 Transgender woman 1 (1.7) 1 (1.7) 0 (0) 2 (3.4) 0 (0) 1 (1.7)
 Gender queer 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.7) 1 (1.7)
Schooling
 Less than secondary 0 (0) 1 (1.7) 1 (1.7) 16 (27.1) 18 (30.0) 7 (11.7)
 Completed secondary 1 (1.7) 7 (11.9) 1 (1.7) 10 (17.0) 19 (31.7) 33 (55.0)
 More than secondary 59 (98.3) 51 (86.4) 57 (96.6) 33 (55.9) 23 (38.3) 20 (33.3)
Employment
 None 8 (13.3) 9 (15.2) 3 (5.1) 40 (67.8) 39 (65.0) 44 (73.3)
 Part-time 2 (3.3) 5 (8.5) 3 (5.1) 6 (10.2) 14 (23.3) 10 (16.7)
 Full-time 50 (83.4) 45 (76.3) 53 (89.8) 13 (22.0) 7 (11.7) 6 (10.0)
Sex partners (past 3 mo)
 0–1 17 (28.3) 16 (27.1) 10 (17.0) 3 (5.1) 4 (6.7) 4 (6.7)
 2–4 19 (31.7) 24 (40.7) 29 (49.2) 30 (50.8) 21 (35.0) 26 (43.3)
 5–9 16 (26.7) 6 (10.2) 11 (18.6) 8 (13.6) 18 (30.0) 18 (30.0)
 ≥10 8 (13.3) 13 (22.0) 9 (15.2) 17 (28.8) 15 (25.0) 12 (20.0)
 Missing 0 (0) 0 (0) 0 (0) 1 (1.7) 2 (3.3) 0 (0)
Anal intercourse without a condom
 No 38 (63.3) 33 (55.9) 42 (71.2) 12 (20.3) 20 (33.3) 10 (16.7)
 Yes 22 (36.7) 26 (44.1) 17 (28.8) 47 (79.7) 40 (66.7) 50 (83.3)
Data are presented as No. (%).
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vs daily) (Table 2). Proportions taking ≥2 tablets on weeks when 
sex was reported did not change over time (P > .14 for all rand-
omization groups).
Numbers of PrEP Tablets Required for Adherence and Numbers Used
Daily dosing was associated with more than twice as many 
tablets required for adherence to the recommended regimen 
(“Tablets Recommended” in Table 2) and larger numbers of tab-
lets actually used compared to both nondaily dosing regimens. 
Median drug concentrations in the daily arms were nearly dou-
ble the concentrations of those in the time-driven and event-
driven arms when sex was reported in the prior week (P < .0001 
for Bangkok, P = .0064 for Harlem; Table 2).
Adherence
In Bangkok, adherence to the recommended regimen in the daily 
and time-driven arms were comparable (85.4% vs 79.4%; P = .42), 
whereas adherence in the event-driven arm was less (65.1%; 
Figure 2. Coverage of sex events with pre- and postsex preexposure prophylaxis dosing in the HIV Prevention Trials Network (HPTN) 067 study, Bangkok, Thailand (A) and 
Harlem, New York (B). Error bars represent the 95% confidence interval of the estimate of coverage, based on bootstrap analysis.
Figure 3. Coverage of sex events with pre- and postsex dosing, the primary outcome, by study site in Bangkok, Thailand (A) and in Harlem, New York (B), showing 4-week 
period and recommended regimen. Each row represents a different participant. Dark blue represents complete coverage of sex events with pre- and postsex dosing. Lighter 
blue shades indicate partial coverage. White represents periods where there was no coverage with pre- or postsex dosing. Black periods reflect periods where there was no 
sexual intercourse reported or data regarding preexposure prophylaxis use or sexual activity was missing.
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P < .0001 vs daily). In Bangkok, ≥90% adherence was evident in 
29 of 60 (48.3%) participants in the daily arm vs 14 of 59 (23.7%) 
in the time-driven arm vs 4 of 59 (6.8%) in the event-driven arm. 
In Harlem, adherence in the daily arm was higher than the time-
driven arm (65.1% vs 46.5%; P < .0001) and the event-driven arm 
(41.3%; P < .0001 vs daily). In Harlem, ≥90% adherence was evi-
dent in 15 of 59 (25.4%) in the daily arm, none of the participants 
in the time-driven arm, and 1 of 59 (1.7%) in the event-driven arm.
In Bangkok, sharing tablets with other trial participants who 
needed them was reported during 6% of interviews in the event 
driven arm and not in other groups. Receiving tablets from other 
participants because of need was reported in 3% of interviews in 
the daily arm and not in other groups. In Harlem, tablet sharing 
was reported during 1%–4% of interviews in all groups.
Self-reported Switching of Regimens
Participants were instructed to follow their specific regimen 
(see Supplementary Materials), although each participant 
received enough tablets to adopt an alternative strategy in prac-
tice. Computer-assisted self-interviews about regimen switch-
ing indicated that the following proportions of participants in 
Bangkok and Harlem intentionally switched regimens during 
the self-administered phase of the study: 12% and 10%, respec-
tively, of the daily arm, 0 and 4%, respectively, of the time-driven 
arm, and 10% and 20%, respectively, of the event-driven arm 
after excluding missing responses (Bangkok, P = .015; Harlem, 
P = .037; overall P = .0010). The adopted regimen varied among 
people who switched.




Daily Time-Driven Event-Driven P Value Daily Time-Driven Event-Driven P Value
No. 60 59 59 … 59 60 60 …
Tablets required for full coverage 1746 1573 1268 .90 1244 1390 1582 .55
Total tablets used (% of daily) 8285 3713 (44.8%) 2157 (26.0%) <.0001 5507 2468 (44.8%) 2356 (42.8%) <.0001
Tablets recommended (% of 
daily)
9420 4121 (43.7%) 1928 (20.5%) <.0001 8222 3674 (44.7%) 2572 (31.3%) <.0001
Recommended tablets used 
(% of daily)
8047 3272 (40.7%) 1255 (15.6%) <.0001 5351 1708 (31.9%) 1063 (19.9%) <.0001
Adherence (tablets used / 
recommended)
85.4% 79.4% 65.1% <.0001 65.1% 46.5% 41.3% <.0001
Adherence category (% of 
group)
<.0001 <.0001
 0 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.7%)
 1%–49% 4 (6.7%) 2 (3.4%) 9 (15.2%) 20 (33.9%) 36 (60.0%) 40 (66.6%)
 50%–89% 27 (45.0%) 43 (72.9%) 45 (76.3%) 24 (40.7%) 22 (36.7%) 15 (25.0%)
 90%–99% 25 (41.6%) 13 (22.0%) 2 (3.4%) 14 (23.7%) 0 (0%) 0 (0%)
 100% 4 (6.7%) 1 (1.7%) 2 (3.4%) 1 (1.7%) 0 (0%) 1 (1.7%)
 No sex 0 (0%) 0 (0%) 1 (1.7%) 0 (0%) 0 (0%) 0 (0%)
 No interview data 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (3.3%) 3 (5.0%)
TFV-DP concentration on weeks when sex is reporteda
 Median 84.3 36.9 29.9 <.0001 316.0 122.5 84.9 .0064
 IQR (64.3–127.0) (22.9–83.0) (18.8–46.4) (0–942.0) (41.8–409.0) (0–202.0)
Visits with TFV-DP concentra-
tions indicating ≥2 tabletsb 
taken per week on weeks 
when sex is reported.
.52 .014
 Week 10 31/31 (100%) 29/29 (100%) 30/30 (100%) 13/23 (56.5%)  8/23 (34.8%) 5/27 (18.5%)
 Week 18  28/29 (96.6%) 30/30 (100%) 24/26 (92.3%) 11/27 (40.7%)  10/27 (37.0%) 3/21 (14.3%)
 Week 30  22/23 (95.7%) 18/19 (94.7%) 13/14 (92.9%) 9/18 (50.0%)  3/18 (16.7%) 3/18 (16.7%)
 Overall 81/83 (97.6%) 77/78 (98.7%) 67/70 (95.7%) 33/68 (48.5%) 21/68 (30.9%) 11/66 (16.7%)
Neurologic side effect, % of 
visits
14.2% 14.3% 13.3% .94 6.1% 3.3% 4.5% .32
Gastrointestinal side effects, % 
of visits
13.1% 8.5% 10.5% .38 8.0% 5.8% 7.1% .75
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: IQR, interquartile range; TFV-DP, tenofovir diphosphate.
aTFV-DP in peripheral blood mononuclear cells (PBMCs) was analyzed for Bangkok, and dried blood spots (DBSs) for Harlem.
bFor Bangkok, TFV-DP in PBMCs >5.2 fmol/106 cells is considered as participants taken ≥2 tablets per week; For Harlem, TFV-DP in DBSs ≥326 fmol/punch is considered as participants 
taken ≥2 tablets per week.
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HIV Infections
Four HIV seroconversions occurred during the study; 3 before 
randomization and 1 after randomization as reported previ-
ously [13]. The postrandomization seroconversion occurred 
after randomization to the daily arm, yet drug concentrations 
indicated use of <1 tablet per week at seroconversion.
Safety and Tolerability
There were no significant differences in side effects by randomi-
zation group at Bangkok and Harlem related to the neurological 
system (P = .94 and P = .32, respectively) or gastroenterologi-
cal system (P = .38 and P = .75, respectively; Table 2; Figure 4). 
However, there were trends toward greater side effects in the 
daily arm at week 10 (4 weeks after randomization) at both 
study sites (Figure 4). Gastrointestinal side effects became less 
frequent after week 10 (P < .0001 at both sites) and neurolog-
ical side effects became less frequent in Bangkok (P  <  .017) 
and did not change in Harlem (P = .091). Creatinine elevations 
(whether confirmed or not) occurred among 16 of 178 (9.0%) 
participants in Bangkok (10, 2, and 4 in the daily, time-driven, 
and event-driven arms, respectively, P  =  .050) and 1 of 179 
(0.5%) in Harlem in the daily arm; all were grade 1 except for 
1 participant in Bangkok in the daily arm who had a grade 2 
elevation. Overall, 10 of 357 (2.8%) participants temporarily 
or permanently discontinued PrEP due to side effects (6/178 
[3.3%] in Bangkok and 4/179 [2.2%] in Harlem). Of these, 5 
were in the daily arm, 4 were in the time-driven arm, and 1 
was in the event-driven arm. No bone fractures were reported 
among participants in Bangkok and 2 fractures were reported in 
2 participants in Harlem, both related to trauma.
DISCUSSION
The overall feasibility of nondaily PrEP in this study differed by 
study site: Nondaily dosing appeared to be feasible among men 
and transgender women who have sex with men in Bangkok, 
as was also seen in the Ipergay trial [3], whereas participants in 
Harlem who received a recommendation for daily dosing did 
substantially better in terms of coverage, adherence, and drug 
concentrations compared with those in Harlem who received 
recommendations for nondaily regimens. In contrast with MSM 
in Bangkok, MSM in Harlem were more similar to women in 
Cape Town [8], where recommendations for daily dosing also 
led to higher levels of coverage of sex acts.
A separate analysis of primary outcomes by site was planned 
based on the premise that social and cultural factors could 
impact behavioral outcomes, including PrEP use before and 
Figure 4. Side effects in the HIV Prevention Trials Network (HPTN) 067 study by randomization group in Bangkok, Thailand (A and B) and Harlem, New York (C and D). 
Neurological side effects include dizziness and headache (A and C). Gastrointestinal side effects include nausea, vomiting, and abdominal cramping (B and D).
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after sexual intercourse. The overall levels of retention in the 
study, PrEP coverage of sex events, adherence, and drug con-
centrations were all higher in Bangkok relative to Harlem. The 
participants at the Bangkok site had more years of schooling 
and greater employment, which may have facilitated participa-
tion in this research study. In addition, the Bangkok site pro-
vides longitudinal clinical services to large numbers of gay and 
bisexual men and transgender women, whereas the Harlem 
site is a dedicated clinical trials facility. Research settings that 
also provide clinical services to nonresearch clients may attract 
more-adherent participants or may foster greater adherence; 
high PrEP adherence has been observed in the context of clin-
ical services and demonstration projects [5, 14–17]. Increased 
PrEP use in Bangkok may also reflect greater familiarity with 
PrEP among clients, more health literacy generally, more iden-
tification with gay communities, less stigma, more trust in med-
ical services, and less access to PrEP outside the study.
Nondaily PrEP use in HPTN 067 did not decrease neu-
rological or gastrological side effects; these symptoms are 
primarily reported in the first weeks of use [18, 19] and may 
reflect a startup syndrome rather than accumulated dose effect. 
Creatinine elevations occurred more frequently in Bangkok 
than Harlem, especially in the daily arm, likely reflecting greater 
PrEP use or smaller body size. The creatinine elevations were 
mild, nonprogressive, and did not require stopping study med-
ication (defined per protocol as estimated creatinine clearance 
≤50 mL/minute or serum creatinine ≥1.5 times the upper limit 
of normal). FTC/TDF PrEP decreases bone mineral density in 
a dose-dependent manner [20], although PrEP trials have not 
demonstrated an impact on bone fractures. Bone mineral dens-
ity was not evaluated in this trial.
A limitation of this study is that it was conducted before the 
results of the Ipergay study were available. Reflecting the infor-
mation available at the time, participants were informed that the 
efficacy of daily oral PrEP was known, whereas nondaily reg-
imens were considered experimental, which may have under-
mined adherence to these regimens. Qualitative information 
collected during this study indicated that belief in PrEP efficacy 
was a powerful facilitator of adherence [21]. Providing infor-
mation about the safety and efficacy of nondaily PrEP for MSM 
from the Ipergay study [3] may increase uptake and adherence to 
nondaily regimens. Another limitation is that participants were 
randomly assigned to the treatment arms, rather than choosing 
the regimen based on their frequency of sex, ability to plan for 
sex, and personal preference. Regimen switching was reported 
by a substantial minority of participants, especially from ran-
domization to the daily and event-driven arms. This may reflect 
individual preferences or changes in sexual practices, which are 
known to change with time [22, 23]. Other limitations of the 
study are that the EDM device was bulky and occasionally lost 
(especially in Harlem), study procedures were burdensome, and 
visits were frequent, all of which created inconvenience that can 
be expected to undermine PrEP use. The duration of self-admin-
istered therapy was too short to evaluate nonpersistence of PrEP 
use. Too few transgender women were enrolled to allow any con-
clusions about their experience with daily vs nondaily regimens.
PrEP has an important role in containing the spread of HIV, 
as reflected in the new World Health Organization recommen-
dation that PrEP should be offered to people at substantial risk 
[24]. PrEP use expanded 3-fold in the United States in 2014 [25, 
26] and has been approved for support by public programs in 
multiple countries. Guiding people on how and when to start 
and stop PrEP as sexual practices and relationships change is an 
emerging challenge, which may be addressed with event-driven 
dosing for some people. For others in this study, a recommenda-
tion for daily PrEP dosing led to protective PrEP drug concentra-
tions among the majority of men and transgender women who 
have sex with men in 2 markedly different settings. How well 
services can be adapted to diverse settings and changing sexual 
practices is a critical determinant of the dissemination of inno-
vations, including PrEP, and their impact on HIV transmission.
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